SCHEMBL6738896

SCHEMBL6738896

N#Cc1ccc(OC[C@@H](O)CN2CC3CC(C2)CN(C(=O)Nc2ccccc2)C3)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
FAAH O00519 2/20 0.48
KCNH2 Q12809 1/20 0.47
SCN1A P35498 1/20 0.47
SCN5A Q14524 1/20 0.47
SCN9A Q15858 1/20 0.47
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GRIN2B Q13224 2/20 0.45
MAPK1 P28482 2/20 0.45
KCNA5 P22460 1/20 0.45
AGER Q15109 1/20 0.45
NAMPT P43490 1/20 0.43
MAPT P10636 2/20 0.42
KDM1A O60341 1/20 0.42
HIF1A Q16665 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739974 0.95 KCNH2 (0.49) MEN1KMT2AFAAHKCNH2TSHR
SCHEMBL6740324 0.92 GRIN2B (0.52) MEN1KMT2AFAAHKCNH2TSHR
SCHEMBL6734803 0.91 GRIN2B (0.54) MEN1KMT2AKCNH2TSHRHSD17B10
SCHEMBL6739331 0.89 KCNH2 (0.46) MEN1KMT2AKCNH2TSHRHSD17B10
SCHEMBL6733219 0.87 KCNH2 (0.49) MEN1KMT2AKCNH2TSHRHSD17B10
SCHEMBL6742664 0.87 MEN1 (0.49) MEN1KMT2AKCNH2TSHRHSD17B10
SCHEMBL6733249 0.86 KCNH2 (0.52) MEN1KMT2AKCNH2HSD17B10KDM4E
SCHEMBL6738575 0.86 KCNH2 (0.52) MEN1KMT2AKCNH2HSD17B10KDM4E
SCHEMBL6619543 0.86 MEN1 (0.53) MEN1KMT2AKCNH2HSD17B10KDM4E
SCHEMBL6622630 0.86 MEN1 (0.53) MEN1KMT2AKCNH2HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229900-A1 Bispidine compounds useful in the treatment of cardiac arrythmias ASTRAZENECA AB (SE) 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229900-A1 Bispidine compounds useful in the treatment of cardiac arrythmias ADRA1B, ADRB2, ADRA1D MEN1 2091/4885KMT2A 3468/4885FAAH 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.